Corcept Therapeutics Inc. is urging the full U.S. Court of Appeals for the Federal Circuit to reconsider a panel’s decision that upheld a lower court’s ruling in favor of Teva Pharmaceuticals USA Inc. regarding the production of a generic version of Korlym, a drug used to treat Cushing’s syndrome. Corcept contends that the panel improperly relied on a 2022 case in its decision.
In February 2026, the Federal Circuit affirmed the District of New Jersey’s December 2023 verdict, which found that Teva’s marketing of a generic Korlym did not infringe upon Corcept’s patents. These patents cover methods for safely co-administering Korlym with strong CYP3A4 inhibitors, a class of drugs commonly prescribed to patients with Cushing’s syndrome. Corcept’s CEO, Dr. Joseph K. Belanoff, expressed disappointment with the ruling, emphasizing the importance of these patents in ensuring safe treatment protocols for patients. ([nasdaq.com](https://www.nasdaq.com/press-release/corcept-provides-update-patent-dispute-teva-pharmaceuticals-2026-02-19?utm_source=openai))
The dispute centers on Corcept’s patents that claim methods of co-administering mifepristone (the active ingredient in Korlym) with strong CYP3A inhibitors to treat Cushing’s syndrome. Teva’s proposed generic label mirrored Corcept’s 2019 Korlym label, which included dosing adjustments for such co-administration. However, the courts determined that the label alone was insufficient to establish direct infringement, especially without evidence that physicians would follow the infringing use. ([mondaq.com](https://www.mondaq.com/unitedstates/patent/1750208/corcept-therapeutics-v-teva-pharmaceuticals-going-outside-the-label-to-show-no-direct-infringement?utm_source=openai))
Following the Federal Circuit’s decision, Corcept’s stock experienced a significant decline, reflecting investor concerns over the potential impact on the company’s revenue stream due to the introduction of a generic competitor. ([investing.com](https://www.investing.com/news/stock-market-news/corcept-therapeutics-stock-falls-after-losing-key-patent-case-appeal-93CH-4514354?utm_source=openai))
Corcept’s request for an en banc rehearing underscores the company’s commitment to defending its intellectual property rights. The outcome of this appeal could have broader implications for pharmaceutical patent litigation, particularly concerning method-of-treatment and drug-drug interaction patents as barriers against generic entry. ([patsnap.com](https://www.patsnap.com/resources/blog/litigation/corcept-v-teva-mifepristone-patent-win-patsnap-eureka/?utm_source=openai))
As the legal proceedings continue, stakeholders in the pharmaceutical industry are closely monitoring the case, recognizing its potential to influence future patent disputes and the balance between innovation and generic competition.